For the year, the portfolio participated strongly, returning 14.28% (investor share), but trailed the index’s 15.91% return.
Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.
Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results